Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Net Cash Flow: 2017-2025

Historic Net Cash Flow for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$216.9 million.

  • Cidara Therapeutics' Net Cash Flow fell 486.55% to -$216.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.6 million, marking a year-over-year increase of 119.27%. This contributed to the annual value of $160.4 million for FY2024, which is 5164.16% up from last year.
  • According to the latest figures from Q3 2025, Cidara Therapeutics' Net Cash Flow is -$216.9 million, which was down 163.35% from $342.4 million recorded in Q2 2025.
  • Cidara Therapeutics' Net Cash Flow's 5-year high stood at $342.4 million during Q2 2025, with a 5-year trough of -$216.9 million in Q3 2025.
  • Over the past 3 years, Cidara Therapeutics' median Net Cash Flow value was -$1.8 million (recorded in 2023), while the average stood at $24.3 million.
  • Within the past 5 years, the most significant YoY rise in Cidara Therapeutics' Net Cash Flow was 5,415.53% (2024), while the steepest drop was 2,001.31% (2024).
  • Over the past 5 years, Cidara Therapeutics' Net Cash Flow (Quarterly) stood at $22.0 million in 2021, then tumbled by 192.62% to -$20.3 million in 2022, then skyrocketed by 36.64% to -$12.9 million in 2023, then spiked by 633.59% to $68.8 million in 2024, then crashed by 486.55% to -$216.9 million in 2025.
  • Its Net Cash Flow stands at -$216.9 million for Q3 2025, versus $342.4 million for Q2 2025 and -$21.7 million for Q1 2025.